REFERENCES
- Gazzard BG. British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral ther-apy 2008. HIV Med. 2008;9(8):563–608.
- Hammer SM, Eron JJ Jr, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA. 2008;300(5):555–570.
- Yeni P, Cooper DA, Aboulker JP, et al. Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial. Lancet. 2006;368(9532):287–298.
- Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: Fall 2006. Top HIV Med. 2006;14(3)125–130.
- Descamps D, Chaix ML, Andre P, et al. French national sen-tinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naive chroni-cally infected patients in 2001-2002. J Acquir Immune Defic Syndr 2005;38(5):545–552.
- Wensing AM, van de Vijver DA, Angarano G, et al. Preva-lence of drug-resistant HIV-1 variants in untreated indi-viduals in Europe: implications for clinical management. J Infect Dis. 2005;192(6):958–966.
- Cane P, Chrystie I, Dunn D, et al. Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ. 2005;331(7529):1368.
- Lohse N, Obel N, Kronborg G, et al. Declining prevalence of HIV-infected individuals at risk of transmitting drug-resistant HIV in Denmark during 1997-2004. Antivir Ther. 2006;11(5):591–600.
- Dunn D, Geretti AM, Green H, et al. Population trends in the prevalence and patterns of protease resistance related to exposure to unboosted and boosted protease inhibi-tors. Antivir Ther 2008;13(6):771–777.
- de Mendoza C, Garrido C, Corral A, et al. Changing rates and patterns of drug resistance mutations in antiretroviral-experienced HIV-infected patients. AIDS Res Hum Retrovi-ruses. 2007;23(7):879–885.
- Chaix ML, Descamps D, Harzic M, et al. Stable prevalence of genotypic drug resistance mutations but increase in non-B virus among patients with primary HIV-1 infection in France. AIDS. 2003;17(18):2635–2643.
- Coetzee D, Hildebrand K, Boulle A, et al. Outcomes after two years of providing antiretroviral treatment in Khayelit-sha, South Africa. AIDS. 2004;18(6):887–895.
- Bocket L, Cheret A, Deuffic-Burban S, et al. Impact of human immunodeficiency virus type 1 subtype on first-line antiretroviral therapy effectiveness. Antivir Ther. 2005;10(2):247–254.
- De Wit S, Boulme R, Poll B, Schmit JC, Clumeck N. Viral load and CD4 cell response to protease inhibitor-containing regimens in subtype B versus non-B treatment-naive HIV-1 patients. AIDS. 2004;18(17):2330–2331.
- Frater AJ, Dunn DT, Beardall AJ, et al. Comparative response of African HIV-1-infected individuals to highly active antiretroviral therapy. AIDS. 2002;16(8): 1139–1146.